PRIMECAP MANAGEMENT CO/CA/PRIMECAP MANAGEMENT CO/CA/

Institutional investor · Portfolio as of Q4 2022

Top Holdings334 positions

Checking export access…
Activity:

Eli Lilly & Co.

25.9M$9.5B8.7%$104.89+238.96%
17 qtrssince 2018-Q4
Decreased
0

BIOGEN INC

15.7M$4.3B4.0%$299.26-7.46%
17 qtrssince 2018-Q4
Decreased
0

Amgen Inc.

15.3M$4B3.7%$154.26+51.59%
17 qtrssince 2018-Q4
Decreased
0

Microsoft Corp.

13.3M$3.2B2.9%$94.43+146.46%
17 qtrssince 2018-Q4
Decreased
0
AZNAZN
ADR

ASTRAZENECA PLC

45M$3.1B2.8%$62.04+105.95%
17 qtrssince 2018-Q4
Decreased
0

Texas Instruments Inc.

17.1M$2.8B2.6%$76.19+94.73%
17 qtrssince 2018-Q4
Decreased
0

KLA Corp.

6.8M$2.6B2.3%$8.13+348.87%
17 qtrssince 2018-Q4
Decreased
0

FEDEX CORP

13.9M$2.4B2.2%$117.29+10.26%
17 qtrssince 2018-Q4
Increased
55

Adobe Inc

6.3M$2.1B2.0%$226.24+48.75%
17 qtrssince 2018-Q4
Decreased
0

Thermo Fisher Scientific Inc

3.7M$2B1.8%$222.42+144.71%
17 qtrssince 2018-Q4
Decreased
0

Micron Technology Inc.

39.7M$2B1.8%$30.95+59.09%
17 qtrssince 2018-Q4
Decreased
0

WELLS FARGO CO NEW

47.7M$2B1.8%$36.98+1.57%
17 qtrssince 2018-Q4
Decreased
0

Alphabet Inc.

21.1M$1.9B1.7%$52.04+67.95%
17 qtrssince 2018-Q4
Decreased
0
SONYSONY
ADR

SONY CORP

24.4M$1.9B1.7%$9.26+62.08%
17 qtrssince 2018-Q4
Decreased
0

BIOMARIN PHARMACEUTICAL INC

17.6M$1.8B1.7%$84.20+22.91%
17 qtrssince 2018-Q4
Decreased
0

SOUTHWEST AIRLS CO

52.2M$1.8B1.6%$41.74-25.94%
17 qtrssince 2018-Q4
Decreased
0

Boston Scientific Corporation

37.7M$1.7B1.6%$35.48+30.41%
17 qtrssince 2018-Q4
Increased
50

BRISTOL-MYERS SQUIBB CO

21.9M$1.6B1.4%$40.67+49.85%
17 qtrssince 2018-Q4
Decreased
0
NVSNVS
ADR

NOVARTIS AG

17.2M$1.6B1.4%$58.53+33.91%
17 qtrssince 2018-Q4
Decreased
0
BABABABA
ADR

ALIBABA GROUP HLDG LTD

17.3M$1.5B1.4%$144.17-42.50%
17 qtrssince 2018-Q4
Decreased
0
$109.2B
AUM
334
Positions
Q4 2022
Filing
HI score · 3.0/5
Quarterly 13F Value Change
-5%Q3'21$141.7B+2%Q4'21$144.5B-8%Q1'22$132.6B-16%Q2'22$111.9B-8%Q3'22$103.3B+6%Q4'22$109.2B
Activity profile
$ moved · Q4'22
New1%Increased18%Decreased78%Exited3%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 3.2 years
<1Q3%1-4Q5%1-2Y11%2Y+81%

PRIMECAP MANAGEMENT CO/CA/ manages $109.2B across 334 positions as of Q4 2022. Top holdings: LLY (8.7%), BIIB (4.0%), AMGN (3.7%). Fund DNA: Steady Compounder. HoldingsIntel Score: 3/5.0.

Q4 2022 Summary

Active quarter - 9 new positions, 10 exits, 54 increased. Top move: FDX (INCREASED, conviction 55). Portfolio: $109.2B across 334 positions.

Top holdings by portfolio weight

Total AUM$109B
LLY8.67%
BIIB3.98%
AMGN3.68%
MSFT2.92%
AZN2.79%
TXN2.58%
KLAC2.34%
FDX2.21%
ADBE1.95%
TMO1.84%
Other1.82%

Portfolio allocation by GICS sector

Sectors11
Healthcare33.18%
Technology25.72%
Industrials11.86%
Consumer Cyclical8.67%
Financial Services8.61%
Communication Services5.02%
Unknown4.56%
Basic Materials0.99%
Energy0.80%
Consumer Defensive0.56%
Other0.02%

Behavioral investing profile

Checking access…
Steady Compounder- primarily Healthcare, Technology, Industrials
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(3.0 / 5.0)
Holdings P&L66
Conviction36
Concentration64
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
COPCOPCONOCOPHILLIPS
Q4 2024 → Q2 2026+7.3M shares+$749.8M
7Q
SCHWSCHWSCHWAB CHARLES CORP
Q4 2024 → Q2 2026+24.1M shares+$2.3B
7Q
USFDUSFDUS Foods Holding Corp
Q4 2024 → Q2 2026+3.7M shares+$389.3M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used